AngioDynamics expands European indications for NanoKnife system By Investing.com
AngioDynamics (NASDAQ:ANGO) has announced an expansion of the European indications for its NanoKnife System, now including soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, specifically for intermediate-risk prostate cancer patients. This move aims to strengthen the company's presence in the European medical technology market by increasing access to its irreversible electroporation (IRE) technology for various oncologic applications. The company also plans to launch the LIVER-IRE Global Registry to support clinical adoption and evidence development.
New tumor option in liver, pancreas, kidney as NanoKnife use widens in Europe
AngioDynamics (NASDAQ: ANGO) has announced expanded European indications for its NanoKnife System, allowing its use for soft tissue ablation in tumors of the liver, pancreas, kidney, and prostate, including intermediate-risk prostate cancer. This expansion increases physician access to the NanoKnife System's irreversible electroporation (IRE) technology for treating difficult-to-resect tumors or those near critical structures. The company will also initiate the LIVER-IRE Global Registry in collaboration with the University of Manchester to further evaluate outcomes for liver tumors.
Bastion Asset Management Inc. Buys 304,960 Shares of AngioDynamics, Inc. $ANGO
Bastion Asset Management Inc. significantly increased its stake in medical instruments supplier AngioDynamics, Inc. by 31.8% in Q3, purchasing 304,960 shares to hold 1,264,003 shares. This makes AngioDynamics its largest holding, valued at $13.44 million and representing 7.7% of Bastion's portfolio. Other institutional investors have also adjusted their holdings in AngioDynamics, which currently trades near $10.97 with a "Moderate Buy" consensus rating and a target price of $19.33.
Responsive Playbooks and the ANGO Inflection
This article analyzes Angiodynamics Inc. (NASDAQ: ANGO) using AI models, identifying strong near-term sentiment with a potential mid-term neutrality and long-term positive bias. It presents three distinct trading strategies—position, momentum breakout, and risk hedging—alongside multi-timeframe signal analysis for various risk profiles. The report highlights an exceptional 50.3:1 risk-reward short setup.
Essex Investment Management Co. LLC Increases Holdings in AngioDynamics, Inc. $ANGO
Essex Investment Management Co. LLC significantly increased its stake in AngioDynamics, Inc. by 41.9% in the third quarter of 2025, now holding 327,396 shares valued at $3.657 million. Despite mixed analyst ratings, with an average "Moderate Buy" and target price of $19.33, institutional investors collectively own 89.43% of AngioDynamics' stock. The medical instruments supplier's shares currently trade around $10.67, with a market capitalization of $439.82 million.
AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Rating of "Moderate Buy" by Analysts
AngioDynamics, Inc. (NASDAQ:ANGO) has received a consensus "Moderate Buy" rating from five research firms, with an average 12-month price target of $19.33. Institutional investors hold 89.43% of the stock, with several firms increasing their stakes, notably Divisadero Street Capital Management LP. The company, a medical technology firm, currently has a market capitalization of $435.3 million and a negative P/E ratio.
Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect?
Shares of AngioDynamics (ANGO) have seen a modest gain recently, but Wall Street analysts project a potential upside of 92.2% with a mean price target of $19.33. While the reliability of price targets can be questionable, strong agreement among analysts and positive earnings estimate revisions, further indicated by a Zacks Rank #1 (Strong Buy), suggest potential for the stock's upside. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.
AngioDynamics, The PERT Consortium Create Investigator-Led Research Fund
AngioDynamics and The PERT Consortium have launched the ALPHA-PE Research Fund, an investigator-led initiative to support independent research into pulmonary embolism (PE). The fund will distribute awards ranging from $50,000 to $750,000 over one to three years to address critical evidence gaps in PE care and improve patient outcomes. This collaboration aims to accelerate the generation of clinically relevant data and advance the understanding and management of PE.
AngioDynamics, PERT back $750k doctor-led pulmonary embolism studies
AngioDynamics and The PERT Consortium® have launched the ALPHA-PE Research Fund, an investigator-led initiative to support independent research on pulmonary embolism (PE) care. The fund will provide awards ranging from $50,000 to $750,000 for studies aimed at addressing critical evidence gaps and improving patient outcomes in PE management. This collaboration seeks to generate real-world data and foster science-driven advancements in the treatment of pulmonary embolism, which affects thousands annually.
AngioDynamics announces CEO transition and leadership retention plan
AngioDynamics has announced a CEO transition plan, with James C. Clemmer remaining in his role until a successor is appointed or November 30, 2026. The company's board also approved retention agreements for its executive leadership team to ensure stability during this transition. ANGO stock currently holds a Hold rating from analysts with a $10.00 price target, while TipRanks’ AI Analyst, Spark, rates it as Neutral due to weak financial performance and bearish technicals, partially offset by positive earnings call signals.
Port Catheter Blood Clot Results in Lawsuit Against Device Manufacturer
An Arizona woman has filed a lawsuit against AngioDynamics Inc. and Navilyst Medical Inc., alleging that their Vortex port catheter caused her to develop blood clots, necessitating its surgical removal. The complaint claims defective design, manufacturing, and misrepresentation of the device's safety, contributing to injuries and additional surgery. This case joins numerous similar lawsuits consolidated in federal court, highlighting ongoing concerns about port catheter failures.
AngioDynamics announces CEO transition and leadership retention plan
AngioDynamics (ANGO) has announced a structured transition plan for the retirement of its President and CEO, James C. Clemmer, who will remain in his role until a successor is appointed or up to November 30, 2026. To ensure stability during this period, the board has approved significant cash retention awards for the executive leadership team. Despite weak financial performance and bearish technicals, the company's Q1 2026 guidance and expectations for full-year cash-flow positivity provide a partial offset, leading to a "Neutral" rating from TipRanks’ AI Analyst, Spark.
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
AngioDynamics, Inc. is convening leading cardiovascular physicians and researchers at its third Cardiovascular Scientific Forum to advance multiple cardiovascular programs. This forum follows recent FDA regulatory milestones, including the approval of the IDE application for the APEX-Return pivotal study and 510(k) clearance for a modified AlphaVac F18 85 System, and the PAVE pilot study for its AngioVac System. The event focuses on physician-led collaboration, clinical evidence development, and real-world application of emerging cardiovascular technologies to address unmet patient needs.
AngioDynamics summit spotlights tools for clots and tough heart infections
AngioDynamics is hosting its third Cardiovascular Scientific Forum from February 6-8, 2026, to foster collaboration among cardiovascular leaders and advance its pipeline. This event follows recent FDA regulatory milestones, including an IDE approval for the APEX-Return study evaluating the AlphaReturn Blood Management System and 510(k) clearance for an expanded AlphaVac F18 85 System. The company also received IDE approval for the PAVE study, investigating the AngioVac System for percutaneous removal of right-heart vegetations in infective endocarditis patients.
Here's Why AngioDynamics (ANGO) Is a Great 'Buy the Bottom' Stock Now
AngioDynamics (ANGO) shows signs of a potential trend reversal, indicated by a hammer chart pattern and bolstered by positive earnings estimate revisions from Wall Street analysts. The company also holds a Zacks Rank #1 (Strong Buy), suggesting it is likely to outperform the market. These factors collectively make ANGO a strong candidate for investors looking to "buy the bottom."
SmartPort Infection Lawsuit Alleges AngioDynamics Catheter Defects Forced Surgical Removal
A new lawsuit has been filed by a New York woman against AngioDynamics Inc. and Navilyst Medical Inc., alleging that a defective SmartPort catheter caused a severe infection and necessitated surgical removal just months after implantation. The plaintiff, Lorrie Smith, claims the manufacturers failed to disclose high failure and infection rates associated with the device. This case joins nearly 300 other similar lawsuits centralized in federal court, highlighting ongoing concerns about AngioDynamics' port catheter designs and their potential to cause serious medical complications.
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
AngioDynamics (ANGO) is recommended for adding to portfolios due to strong prospects with its NanoKnife technology and focus on cancer treatment, as well as a broad product line, and solid recent financial performance. Despite some macroeconomic concerns like tariff expenses, the company's growth is driven by increasing adoption of its products in key medical procedures and a positive estimate revision trend for fiscal 2026. The stock is a Zacks Rank #1 (Strong Buy) and has shown significant earnings surprises.
Zacks Research Cuts Earnings Estimates for AngioDynamics
Zacks Research has lowered its near-term earnings estimates for AngioDynamics (NASDAQ: ANGO) for Q3 and Q4 2026, forecasting EPS of ($0.10) and ($0.07) respectively, though it raised its FY2027 estimate to ($0.13). Despite a recent earnings miss, the medical instruments supplier maintains a "Strong-Buy" rating from Zacks, with other analysts giving a "Moderate Buy" consensus and an average target price of $19.33. The company's stock trades near $10, with institutional investors holding approximately 89.4% of shares.
AngioDynamics to lay off 54 workers in Glens Falls, Queensbury
AngioDynamics, a medical device company, is set to lay off 54 employees across its Glens Falls and Queensbury facilities. This decision is part of ongoing efforts to streamline operations and improve efficiency. The layoffs are expected to impact various departments as the company realigns its strategic priorities.
The Technical Signals Behind (ANGO) That Institutions Follow
Angiodynamics Inc. (NASDAQ: ANGO) is showing positive near-term sentiment with a strong long-term outlook, despite a weak mid-term bias. Technical analysis from Stock Traders Daily highlights key support and resistance levels, indicating a significant risk-reward setup targeting a 15.2% gain against a 0.3% risk. AI-generated trading strategies are provided for different risk profiles, including position trading, momentum breakout, and risk hedging.
The Zacks Analyst Blog Highlights AngioDynamics, Boston Scientific and Medtronic
This Zacks Analyst Blog highlights AngioDynamics, Boston Scientific, and Medtronic as three MedTech companies benefiting from favorable product mix shifts. These companies are strategically enhancing their portfolios by focusing on higher-margin, faster-growing, or more differentiated therapies, leading to improved earnings quality, margin expansion, and valuation resilience. The article delves into each company's specific strategies and their financial implications.
AngioDynamics Inc Presents at J.P. Morgan Healthcare Conference
AngioDynamics Inc's CEO, James Clemmer, presented at the J.P. Morgan 44th Annual Healthcare Conference, highlighting the company's MedTech growth strategy. Key achievements include the success of Auryon and the potential of NanoKnife for prostate cancer treatment. The company also provided positive FY2026 financial guidance and emphasized its strong, debt-free balance sheet.
AngioDynamics to lay off 54 workers in Glens Falls, Queensbury
AngioDynamics, a medical device manufacturing company, plans to lay off 54 workers in Glens Falls and Queensbury, New York, starting February 27, 2026. The layoffs are due to "contract loss" and affect nonunion employees across three sites. This follows a previous announcement in 2024 to close these sites to save $15 million, though the company later decided to retain most of its workforce in Warren County, citing strong performance.
Q3 EPS Estimates for AngioDynamics Lowered by HC Wainwright
HC Wainwright has lowered its Q3 2026 EPS estimate for AngioDynamics (NASDAQ: ANGO) to ($0.11), with full-year 2026 EPS now projected at ($0.28). This revision follows AngioDynamics reporting Q1 EPS of ($0.15), missing consensus estimates, despite revenue beating projections and increasing by 9.1% year-over-year. The medical instruments supplier has a consensus analyst rating of "Moderate Buy" with a target price of $19.33, and notable insider buying was recently observed.
Severe Sepsis Infection Leads to Vortex Port Catheter Wrongful Death Lawsuit
A wrongful death lawsuit has been filed against AngioDynamics and Navilyst Medical, alleging that a defective Vortex port catheter contributed to a Wisconsin woman's death from sepsis. The lawsuit claims that design flaws, known to the manufacturers, led to microfractures and infection, prioritizing profits over patient safety. This case joins approximately 300 other AngioDynamics port catheter lawsuits consolidated in federal court, with bellwether trials anticipated to influence settlement negotiations.
Down 25.0% in 4 Weeks, Here's Why You Should You Buy the Dip in AngioDynamics (ANGO)
AngioDynamics (ANGO) stock has recently declined by 25% over the past four weeks, making it an attractive "buy the dip" opportunity. The stock is considered oversold based on its Relative Strength Index (RSI) of 22.62, and analysts have a strong consensus for improved earnings, revising EPS estimates up by 3.6% in the last 30 days. Additionally, ANGO holds a Zacks Rank #1 (Strong Buy), indicating a potential turnaround in the near term.
Assessing AngioDynamics (ANGO) Valuation After Raised Guidance And Med Tech Momentum
AngioDynamics (ANGO) has seen its share price perform well recently due to strong quarterly results driven by its Med Tech platforms, leading to raised revenue and profitability guidance. Despite a recent share price pullback, analysts consider the stock 44.9% undervalued with a fair value of $18.25 versus its current price of $10.05, based on assumptions of accelerated adoption of higher-margin products and future reimbursement enhancements. However, this valuation could be challenged by tariff pressures or delays in regulatory approvals.
Assessing AngioDynamics (ANGO) Valuation After Raised Guidance And Med Tech Momentum
AngioDynamics (ANGO) has seen its valuation come under scrutiny after strong quarterly results, driven by its Med Tech platforms, led to raised guidance for the full year. Despite recent positive momentum in share price, the stock is considered significantly undervalued by analysts, trading at US$10.05 against a fair value estimate of US$18.25. This valuation gap is supported by expectations of accelerated adoption of higher-margin products due to ongoing clinical validation and upcoming reimbursement enhancements.
Why AngioDynamics stock is sinking today
This article from MSN discusses the reasons behind the decline in AngioDynamics (ANGO) stock. Due to the incomplete content provided, no further details on the specific causes of the stock's performance can be given.
Assessing AngioDynamics (ANGO) Valuation After Raised Guidance And Med Tech Momentum
AngioDynamics (ANGO) has seen its valuation in the spotlight after raising its full-year guidance due to stronger quarterly results from its Med Tech platforms. Despite recent share price momentum fading, the company is considered "44.9% Undervalued" with a fair value estimate of US$18.25 against its current trading price of US$10.05, based on assumptions of growth, improved margins, and upcoming reimbursement enhancements for high-margin products like NanoKnife and AlphaVac. However, this narrative could face challenges from tariff pressures or regulatory delays.
AngioDynamics: Fiscal Q2 Earnings Snapshot
AngioDynamics Inc. (ANGO) reported a fiscal second-quarter loss of $6.4 million, or 15 cents per share, adjusting to less than 1 cent per share for specific costs. The medical device maker announced revenue of $79.4 million and anticipates full-year losses between 23 to 33 cents per share, with revenue guidance of $312 million to $314 million. Its shares have grown 3% year-to-date and 46% over the past 12 months.
AngioDynamics (ANGO) EPS Loss Of US$0.26 Tests Optimistic Profit Turnaround Narratives
AngioDynamics (ANGO) reported a Q1 2026 EPS loss of US$0.26 and revenue of US$75.7 million, maintaining focus on its path to profitability. The company has sustained trailing twelve-month losses of US$32.1 million, despite analyst expectations for a shift to profit within three years and forecasted earnings growth of 81.93% annually. The stock trades at a lower price-to-sales multiple compared to the industry, reflecting the challenge of translating growth drivers into actual profitability, while operational savings initiatives aim to close the current earnings gap.
Earnings Summary: AngioDynamics (ANGO) Q2 FY26 sales increase 8.8%
AngioDynamics (ANGO) reported an 8.8% increase in net sales for Q2 fiscal year 2026, reaching $79.4 million. The company incurred a net loss of $6.4 million but reported break-even on an adjusted basis. AngioDynamics also raised its FY26 net sales guidance to $312-314 million.
AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2026 Earnings Call Transcript
AngioDynamics (NASDAQ: ANGO) reported strong Q2 2026 results with revenue up 8.8% and adjusted EBITDA nearly doubling year-over-year, leading to raised full-year guidance. The company saw robust growth in its Med Tech segment, particularly Auryon and NanoKnife, and significant regulatory milestones for its mechanical thrombectomy platforms. CEO Jim Clemmer also announced his intention to retire after a decade, with a search for his successor underway.
AngioDynamics: Fiscal Second Quarter Earnings Overview
AngioDynamics Inc. reported a net loss of $6.4 million, or $0.15 per share, for its fiscal second quarter, with an adjusted loss per share of less than one cent. The medical technology firm generated $79.4 million in revenue and projects future annual losses between $0.33 and $0.23 per share on revenues of $312 million to $314 million. Despite the losses, AngioDynamics' stock has seen a 3% increase year-to-date and a 46% gain over the past year.
AngioDynamics shares jump over 9% as Med Tech segment drives earnings beat
AngioDynamics (NASDAQ:ANGO) shares surged over 9% after the company reported second-quarter fiscal 2026 results that exceeded analyst expectations. The beat was driven by strong performance in its Med Tech segment, leading the company to raise its full-year fiscal 2026 guidance. CEO Jim Clemmer also announced plans to retire in fiscal year 2027.
ANGIODYNAMICS Q2 2026 Earnings Preview: Recent $ANGO Insider Trading, Hedge Fund Activity, and More
ANGIODYNAMICS ($ANGO) is set to release its Q2 2026 earnings on January 6th, with analysts forecasting $77.8M in revenue and -$0.10 EPS. The article provides an overview of recent insider trading, hedge fund movements, government contracts, congressional stock trading, and analyst ratings for the company. Key insider purchases and significant hedge fund portfolio adjustments are highlighted.
AngioDynamics Vortex Failure Led to Port Catheter Removal, Lawsuit
A Georgia man has filed a lawsuit against AngioDynamics, alleging that his Vortex port catheter failed, became infected, and required surgical removal. The complaint is one of many port catheter lawsuits claiming defective design and prone-to-failure implants from AngioDynamics and Navilyst Medical. The lawsuit calls for a recall of the Vortex port catheters, citing the company's alleged longtime knowledge of the risks without adequate warning to the medical community.
AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
AngioDynamics, Inc. (NASDAQ: ANGO) is set to release its Q2 earnings on January 6, 2026, with analysts expecting a quarterly loss of 10 cents per share on revenues of $76.43 million. Analysts William Plovanic of Canaccord Genuity and Yi Chen of HC Wainwright & Co. have maintained Buy ratings on the stock, with Plovanic raising his price target to $18. The company previously raised its FY26 adjusted EPS guidance in October.
AngioDynamics (ANGO) to Release Earnings on Tuesday
AngioDynamics (NASDAQ: ANGO) is scheduled to report its Q2 2026 earnings before market open on Tuesday, January 6, 2026. Analysts anticipate earnings of ($0.10) per share and revenue of $76.43 million, with the company guiding FY 2026 EPS at -0.33 to -0.23. The medical instruments supplier exceeded estimates in the prior quarter, reporting ($0.10) EPS and $75.71 million in revenue, an increase of 12.1% year-over-year.
AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
AngioDynamics Inc. (NASDAQ: ANGO) is set to release its Q2 earnings on January 6, 2026, with analysts anticipating a quarterly loss of 10 cents per share on revenue of $76.43 million. Ahead of the earnings call, top analysts William Plovanic of Canaccord Genuity and Yi Chen of HC Wainwright & Co. have reiterated Buy ratings, with Plovanic raising his price target to $18. The company previously raised its FY26 adjusted EPS guidance in October.
Technical Reactions to ANGO Trends in Macro Strategies
This article provides a technical analysis of Angiodynamics Inc. (NASDAQ: ANGO), highlighting weak near-term sentiment that could challenge long-term strength. It outlines specific trading strategies including position trading, momentum breakout, and risk hedging, based on AI-generated signals and multi-timeframe analysis. The report also details immediate risk-reward setups for traders.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
AngioDynamics Inc. (ANGO) is gaining momentum due to strong prospects with its NanoKnife technology and an increased focus on cancer treatment markets. The company reported a solid first-quarter fiscal 2026 performance with double-digit revenue growth in key segments and positive ongoing studies. Despite macroeconomic concerns like tariffs, AngioDynamics expects continued business improvements, making it a compelling option for investors.
United States - Cadwalader Secures Federal Circuit Win Affirming Invalidation Of Bard’s Vascular Access Port Patents For AngioDynamics
Cadwalader achieved a significant victory for its client AngioDynamics, with the Federal Circuit affirming the invalidation of C.R. Bard's patents related to power-injectable vascular access ports. This win concludes over 12 years of litigation, spanning two jury trials and two appeals, solidifying the invalidation for anticipation. The court sided with AngioDynamics' arguments and evidence, highlighting the cross-examinations and admissions presented by the Cadwalader legal team.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
AngioDynamics (ANGO) is recommended as a stock to hold due to its strong performance with NanoKnife technology, particularly in prostate cancer treatment, and a broad product line including Auryon and thrombectomy devices. The company's solid first-quarter fiscal 2026 results and positive outlook for continued growth are key drivers,尽管面临关税压力，但通过成本控制和产品组合优化，毛利率仍有所改善.
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
AngioDynamics, Inc. announced it will report its fiscal year 2026 second quarter financial results before the market opens on Tuesday, January 6, 2026. The company's management will host a conference call on the same day at 8:00 AM ET to discuss these results. Access to the conference call and a webcast replay will be available through the Investors section of the AngioDynamics website.
Medical tech company sets Jan. 6 call to share latest quarter
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its fiscal year 2026 second-quarter financial results on January 6, 2026, before the market opens. Management will host a conference call at 8:00 AM ET on the same day to discuss the results, with details provided for domestic and international participation, as well as webcast access. The company focuses on medical technologies for vascular systems, cancer treatment, and patient quality of life.
AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference
AngioDynamics, Inc. announced that its President and CEO, Jim Clemmer, and Executive Vice President and CFO, Stephen Trowbridge, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will begin at 3:00 p.m. PT and a live webcast will be available via the company's website. AngioDynamics is a medical technology company focused on vascular systems and cancer treatment.
New York medtech firm to present at J.P. Morgan healthcare conference
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its President and CEO, Jim Clemmer, and Executive Vice President and CFO, Stephen Trowbridge, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be held in San Francisco and a live webcast will be available via the company's website. AngioDynamics is a medical technology company focused on vascular systems and cancer treatment.
Discipline and Rules-Based Execution in ANGO Response
This article provides a detailed analysis of Angiodynamics Inc. (NASDAQ: ANGO), highlighting a near-term neutral sentiment amidst mid and long-term strength. It presents AI-generated institutional trading strategies包括 position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for informed decision-making. Investors can access real-time signals and customized risk models.
